Combined Therapy of Diabetic Peripheral Neuropathy with Breviscapine and Mecobalamin: A Systematic Review and a Meta-Analysis of Chinese Studies

Table 1

Characteristics of included studies.

Trial	Number	Age (Y)	Duration of diabetes (Y)	Duration of DPN (Y)	Treatment drugs/day			Main outcome measures	Course of treatment	Adverse events
					B + M		M
	(B + M/M)	(B + M/M)	(B + M/M)	(B + M/M)	B + M	M
Shi et al. (2013) [25]	90 (45/45)	58.4 ± 11.2/57.9 ± 10.8	11.2 ± 2.3/10.7 ± 2.6	3.01 ± 0.93/3.15 ± 0.87	50 mg iv.	1.5 mg n.r.	1.5 mg n.r.	TER, SNCV, MNCV	6 w	0
Lan and Wu (2010) [26]	82 (43/39)	53.2 ± 3.7/53.6 ± 3.6	9.3 ± 8.3/9.54 ± 3.1	4.3 ± 1.3/4.2 ± 1.2	150 mg ivgtt.	0.5 mg im.	0.5 mg im.	TER, SNCV	4 w	n.r.
Chang (2007) [29]	86 (43/43)	69.4/63.7	12.0/11.0	4/3.5	40 mL ivgtt.	0.5 mg po.	0.5 mg po.	TER, SNCV, MNCV	30 d	5/0
Chen and Shao (2008) [30]	132 (68/64)	72 ± 12.3/69 ± 11.9	n.r.	n.r.	30 mL ivgtt.	1.5 mg po.	1.5 mg po.	TER	2 w	2/0
Duan and Yan (2004) [31]	64 (36/28)	55.5 ± 5.2	5.5 ± 4.2/n.r.	3.6 ± 2.5/n.r.	30 mL ivgtt.	0.5 mg im.	0.5 mg im.	TER, SNCV, MNCV	6 w	n.r.
Feng et al. (2009) [32]	91 (46/45)	n.r.	n.r.	n.r.	20 mL ivgtt.	1.0 mg ivgtt.	1.0 mg ivgtt.	TER	4 w	n.r.
Jin et al. (2010) [33]	70 (35/35)	57 ± 10/56 ± 10	8.5 ± 3.4/8.5 ± 3.2	n.r.	20 mL ivgtt.	0.5 mg im.	0.5 mg im.	TER, SNCV, MNCV	4 w	n.r.
Lan et al. (2007) [34]	82 (43/39)	53.2 ± 3.7/53.6 ± 3.6	9.3 ± 8.3/9.54 ± 8.1	4.3 ± 1.3/4.2 ± 1.2	150 mg ivgtt.	0.5 mg im.	0.5 mg im.	TER, SNCV	4 w	n.r.
Li et al. (2009) [28]	120 (64/56)	60 ± 6.52/60.5 ± 8.33	5.5 ± 4.2	2.6 ± 0.4/2.8 ± 0.5	20 mL ivgtt.	0.5 mg im.	0.5 mg im.	TER, SNCV, MNCV	4 w	0
Li et al. (2006) [35]	56 (29/27)	55 ± 3/56 ± 4	6.75 ± 1.2/6.8 ± 1.2	2.15 ± 0.21/1.98 ± 0.23	135 mg ivgtt.	1.5 mg po.	1.5 mg po.	TER	4 w	2/0
Luo and Tang (2013) [36]	80 (40/40)	61.3 ± 12.08/62 ± 11.87	3.02 ± 1.75/3.04 ± 1.93	5.57 ± 2.03/5.42 ± 2.2	70 mg ivgtt.	1.0 mg iv.	1.0 mg iv.	TER, SNCV, MNCV	2 w	n.r.
Peng et al. (2012) [37]	88 (40/48)	61.56 ± 12.18/62.36 ± 6.25	11.83 ± 2.3/12.04 ± 4.52	4.9/5.5	75 mg ivgtt.	1.0 mg ivgtt.	1.0 mg ivgtt.	TER, SNCV, MNCV	2 w	n.r.
Sun (2014) [38]	60 (30/30)	53.2 ± 3.6/51.7 ± 2.8	10.6 ± 4.2/9.5 ± 3.4	n.r.	20 mL ivgtt.	1.0 mg ivgtt.	1.0 mg ivgtt.	TER, SNCV, MNCV	2 w	n.r.
Wang (2013) [39]	68 (34/34)	62.4 ± 8.4	n.r.	n.r.	200 mg ivgtt.	1.5 mg po.	1.5 mg po.	TER	4 w	2.0/3.0
Wu and Zhang (2007) [40]	74 (38/36)	48/47	7.34/7.28	2.32/2.24	40 mL ivgtt.	500 mL im.	500 mL im.	TER	2–6 w	n.r.
Zhang (2012) [41]	60 (30/30)	59.06 ± 7.82	7.15 ± 1.32	2.06 ± 0.59	50 mg ivgtt.	1.5 mg po.	1.5 mg po.	TER	4 w	0
Zhou (2009) [42]	65 (33/32)	n.r.	n.r.	n.r.	40 mL ivgtt.	1.5 mg po.	1.5 mg po.	TER	4 w	0